^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Colon Cancer
    Regimen: (oxaliplatin + capecitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    07/20/2020
    Excerpt:
    Recommendations: For High risk stage III colon cancer…with MSI or MSS…FOLFOX for 6 months and CAPOX for 6 months. For low risk stage III colon cancer...with MSI or MSS…FOLFOX for 6 months and CAPOX for 3 months (Fig-3).
    DOI:
    10.1016/j.annonc.2020.06.022